Indacaterol
Arcapta Neohaler, Hirobriz Breezhaler, Onbrez Breezhaler, Oslif Breezhaler (indacaterol) is a small molecule pharmaceutical. Indacaterol was first approved as Arcapta Neohaler on 2009-11-29. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against beta-2 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor. Hirobriz breezhaler, onbrez breezhaler, oslif breezhaler's patents are valid until 2028-10-11 (FDA).
Trade Name | Hirobriz Breezhaler, Onbrez Breezhaler, Oslif Breezhaler |
---|---|
Common Name | Indacaterol |
Indication | chronic bronchitis, chronic obstructive pulmonary disease, pulmonary emphysema |
Drug Class | Bronchodilators (phenethylamine derivatives) |